PHP
VRNA

Parkman Healthcare Partners’s Verona Pharma VRNA Stock Holding History

Parkman Healthcare Partners’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-197,898
Closed -$18.7M – 101
2025
Q2 		$18.7M Sell
197,898
-62,523
-24% -$4.63M 2.15% 15
2025
Q1 		$16.5M Sell
260,421
-460,236
-64% -$27.5M 1.96% 17
2024
Q4 		$33.5M Buy
720,657
+94,205
+15% +$3.54M 4.46% 2
2024
Q3 		$18M Buy
626,452
+31,063
+5% +$764K 2.3% 10
2024
Q2 		$8.61M Buy
595,389
+65,869
+12% +$962K 1.15% 33
2024
Q1 		$8.52M Buy
529,520
+24,778
+5% +$428K 1.05% 35
2023
Q4 		$10M Buy
504,742
+86,809
+21% +$1.28M 1.41% 23
2023
Q3 		$6.81M Buy
417,933
+16,946
+4% +$326K 1.25% 27
2023
Q2 		$8.48M Sell
400,987
-87,008
-18% -$1.86M 1.47% 22
2023
Q1 		$9.8M Buy
487,995
+73,547
+18% +$1.59M 2.13% 14
2022
Q4 		$10.8M Buy
414,448
+91,175
+28% +$1.21M 2.88% 6
2022
Q3 		$3.3M Buy
+323,273
New +$2.72M 0.94% 38

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Parkman Healthcare Partners's VRNA Position: Q3 2025 in Review

Parkman Healthcare Partners sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 197,898 shares — an estimated $18.7M sold.

Parkman Healthcare Partners first reported a position in VRNA in Q3 2022 and held it in 12 quarters. The position peaked at $33.5M in Q4 2024. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Parkman Healthcare Partners reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Parkman Healthcare Partners sold 197,898 Verona Pharma shares in Q3 2025, an estimated $18.7M.
  • Parkman Healthcare Partners first reported a position in Verona Pharma in Q3 2022 and held it in 12 quarters.
  • Parkman Healthcare Partners's Verona Pharma position peaked at $33.5M in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Parkman Healthcare Partners's 13F filing for Q3 2025, filed 14 Nov 2025.